Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
CRDF Stock Chart & Stats
$1.73
-$0.21(-4.99%)
At close: 4:00 PM EST
$1.73
-$0.21(-4.99%)
Day’s Range― - ―
52-Week Range$1.48 - $4.56
Previous CloseN/A
Volume446.20K
Average Volume (3M)657.91K
Market Cap
$118.27M
Enterprise Value$101.63M
Total Cash (Recent Filing)$58.30M
Total Debt (Recent Filing)$832.00K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Apr 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding68,364,980
10 Day Avg. Volume538,054
30 Day Avg. Volume657,912
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue171.39
Enterprise Value/Gross Profit-9.07
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$7.43Price Target Upside329.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$357.00K
Bulls Say, Bears Say
Bulls Say
Mechanism And Combination ActivityOnvansertib's dual mechanism—PLK1 inhibition and blockade of tumor survival pathways—appears to increase activity when combined with standard chemotherapy and a targeted agent, strengthening the scientific rationale for further development.
Phase 2 Clinical EfficacyHigher-dose onvansertib produced meaningfully higher tumor response rates and favorable progression-free survival trends versus chemotherapy plus bevacizumab, supporting advancement toward a registrational Phase 3 trial.
Regulatory StatusFast Track designation from the U.S. Food and Drug Administration for onvansertib in second-line KRAS-mutated metastatic colorectal cancer supports an expedited review path and elevated regulatory engagement.
Bears Say
Clinical And Market UncertaintySmall patient cohorts, variability between chemotherapy backbones, and limited use of the selected chemotherapy regimen in frontline practice create uncertainty around confirmatory trial outcomes and commercial uptake.
Funding And Dilution RiskReported net losses and limited cash resources point to a need for additional capital to fund a pivotal trial, increasing the likelihood of dilutive financing or the need for strategic partnerships.
Leadership RiskAbrupt resignations of the CEO and CFO with only an interim chief executive in place create leadership uncertainty that could disrupt strategic execution and investor confidence.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.48 and its highest was $4.55 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $118.27M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Apr 30, 2026 which is in 34 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Feb 24, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.079.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 68,364,980 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went up 12.353%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.43 (329.48% Upside)
$7.43 (329.48% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 5.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.47%
12-Months-Change
Fundamentals
Return on Equity
-82.00%
Trailing 12-Months
Asset Growth
-36.33%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$7.43
▲(329.48% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
4.17% Insiders
7.22% Mutual Funds
13.71% Other Institutional Investors
66.82% Public Companies and Individual Investors